Leerink Partners Thinks Vericel’s Stock is Going to Recover

In a report issued on January 24, Danielle Antalffy from Leerink Partners maintained a Buy rating on Vericel (VCELResearch Report), with a price target of $40.00. The company’s shares closed last Thursday at $35.44, close to its 52-week low of $31.37.

According to, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $48.75, representing a 38.0% upside. In a report issued on January 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $53.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Vericel’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $34.51 million and GAAP net loss of $4.93 million. In comparison, last year the company earned revenue of $32.26 million and had a net profit of $3.62 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Read More on VCEL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More